Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis

Takekazu Iwata, Shigetoshi Yoshida, Kaoru Nagato, Takahiro Nakajima, Hidemi Suzuki, Tetsuzo Tagawa, Teruaki Mizobuchi, Satoshi Ota, Yukio Nakatani, Ichiro Yoshino

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Purpose: Idiopathic pulmonary fibrosis (IPF) is a progressive diffuse lung disease associated with an increased risk of lung cancer. Patients with IPF sometimes develop a life-threatening acute exacerbation of IPF (AE-IPF) after lung cancer surgery. In this retrospective study, pirfenidone, an antifibrotic agent, was perioperatively administered to IPF patients with lung cancer with the aim of preventing postoperative AE-IPF, and the feasibility and clinical outcomes were investigated. Methods: Twelve IPF patients with concomitant lung cancer who received perioperative pirfenidone treatment (PPT) for lung cancer surgery were retrospectively investigated. Sixteen IPF patients undergoing lung cancer surgery without PPT were analyzed as historical controls. Results: Compared to the controls, the PPT patients had a more severely impaired preoperative pulmonary function and a larger number of limited pulmonary resections. There was a significant preoperative decrease in the serum KL-6 levels of the PPT patients. No severe pirfenidone-related complications or IPF-related events occurred in the PPT patients, while six control patients developed AE-IPF (P = 0.0167). A quantitative histopathological evaluation of resected lung specimens found that tissue changes associated with IPF were significantly fewer in the PPT patients (P = 0.021). Conclusions: PPT is a feasible perioperative treatment for IPF patients with lung cancer. Its effectiveness in preventing postoperative AE-IPF thus warrants prospective verification.

Original languageEnglish
Pages (from-to)1263-1270
Number of pages8
JournalSurgery today
Volume45
Issue number10
DOIs
Publication statusPublished - Oct 14 2015
Externally publishedYes

Fingerprint

Idiopathic Pulmonary Fibrosis
Lung Neoplasms
Therapeutics
Lung
pirfenidone
Lung Diseases
Retrospective Studies

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis. / Iwata, Takekazu; Yoshida, Shigetoshi; Nagato, Kaoru; Nakajima, Takahiro; Suzuki, Hidemi; Tagawa, Tetsuzo; Mizobuchi, Teruaki; Ota, Satoshi; Nakatani, Yukio; Yoshino, Ichiro.

In: Surgery today, Vol. 45, No. 10, 14.10.2015, p. 1263-1270.

Research output: Contribution to journalArticle

Iwata, T, Yoshida, S, Nagato, K, Nakajima, T, Suzuki, H, Tagawa, T, Mizobuchi, T, Ota, S, Nakatani, Y & Yoshino, I 2015, 'Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis', Surgery today, vol. 45, no. 10, pp. 1263-1270. https://doi.org/10.1007/s00595-014-1071-5
Iwata, Takekazu ; Yoshida, Shigetoshi ; Nagato, Kaoru ; Nakajima, Takahiro ; Suzuki, Hidemi ; Tagawa, Tetsuzo ; Mizobuchi, Teruaki ; Ota, Satoshi ; Nakatani, Yukio ; Yoshino, Ichiro. / Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis. In: Surgery today. 2015 ; Vol. 45, No. 10. pp. 1263-1270.
@article{3873ee04cc1540acac5158d7dba49301,
title = "Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis",
abstract = "Purpose: Idiopathic pulmonary fibrosis (IPF) is a progressive diffuse lung disease associated with an increased risk of lung cancer. Patients with IPF sometimes develop a life-threatening acute exacerbation of IPF (AE-IPF) after lung cancer surgery. In this retrospective study, pirfenidone, an antifibrotic agent, was perioperatively administered to IPF patients with lung cancer with the aim of preventing postoperative AE-IPF, and the feasibility and clinical outcomes were investigated. Methods: Twelve IPF patients with concomitant lung cancer who received perioperative pirfenidone treatment (PPT) for lung cancer surgery were retrospectively investigated. Sixteen IPF patients undergoing lung cancer surgery without PPT were analyzed as historical controls. Results: Compared to the controls, the PPT patients had a more severely impaired preoperative pulmonary function and a larger number of limited pulmonary resections. There was a significant preoperative decrease in the serum KL-6 levels of the PPT patients. No severe pirfenidone-related complications or IPF-related events occurred in the PPT patients, while six control patients developed AE-IPF (P = 0.0167). A quantitative histopathological evaluation of resected lung specimens found that tissue changes associated with IPF were significantly fewer in the PPT patients (P = 0.021). Conclusions: PPT is a feasible perioperative treatment for IPF patients with lung cancer. Its effectiveness in preventing postoperative AE-IPF thus warrants prospective verification.",
author = "Takekazu Iwata and Shigetoshi Yoshida and Kaoru Nagato and Takahiro Nakajima and Hidemi Suzuki and Tetsuzo Tagawa and Teruaki Mizobuchi and Satoshi Ota and Yukio Nakatani and Ichiro Yoshino",
year = "2015",
month = "10",
day = "14",
doi = "10.1007/s00595-014-1071-5",
language = "English",
volume = "45",
pages = "1263--1270",
journal = "Surgery Today",
issn = "0941-1291",
publisher = "Springer Japan",
number = "10",

}

TY - JOUR

T1 - Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis

AU - Iwata, Takekazu

AU - Yoshida, Shigetoshi

AU - Nagato, Kaoru

AU - Nakajima, Takahiro

AU - Suzuki, Hidemi

AU - Tagawa, Tetsuzo

AU - Mizobuchi, Teruaki

AU - Ota, Satoshi

AU - Nakatani, Yukio

AU - Yoshino, Ichiro

PY - 2015/10/14

Y1 - 2015/10/14

N2 - Purpose: Idiopathic pulmonary fibrosis (IPF) is a progressive diffuse lung disease associated with an increased risk of lung cancer. Patients with IPF sometimes develop a life-threatening acute exacerbation of IPF (AE-IPF) after lung cancer surgery. In this retrospective study, pirfenidone, an antifibrotic agent, was perioperatively administered to IPF patients with lung cancer with the aim of preventing postoperative AE-IPF, and the feasibility and clinical outcomes were investigated. Methods: Twelve IPF patients with concomitant lung cancer who received perioperative pirfenidone treatment (PPT) for lung cancer surgery were retrospectively investigated. Sixteen IPF patients undergoing lung cancer surgery without PPT were analyzed as historical controls. Results: Compared to the controls, the PPT patients had a more severely impaired preoperative pulmonary function and a larger number of limited pulmonary resections. There was a significant preoperative decrease in the serum KL-6 levels of the PPT patients. No severe pirfenidone-related complications or IPF-related events occurred in the PPT patients, while six control patients developed AE-IPF (P = 0.0167). A quantitative histopathological evaluation of resected lung specimens found that tissue changes associated with IPF were significantly fewer in the PPT patients (P = 0.021). Conclusions: PPT is a feasible perioperative treatment for IPF patients with lung cancer. Its effectiveness in preventing postoperative AE-IPF thus warrants prospective verification.

AB - Purpose: Idiopathic pulmonary fibrosis (IPF) is a progressive diffuse lung disease associated with an increased risk of lung cancer. Patients with IPF sometimes develop a life-threatening acute exacerbation of IPF (AE-IPF) after lung cancer surgery. In this retrospective study, pirfenidone, an antifibrotic agent, was perioperatively administered to IPF patients with lung cancer with the aim of preventing postoperative AE-IPF, and the feasibility and clinical outcomes were investigated. Methods: Twelve IPF patients with concomitant lung cancer who received perioperative pirfenidone treatment (PPT) for lung cancer surgery were retrospectively investigated. Sixteen IPF patients undergoing lung cancer surgery without PPT were analyzed as historical controls. Results: Compared to the controls, the PPT patients had a more severely impaired preoperative pulmonary function and a larger number of limited pulmonary resections. There was a significant preoperative decrease in the serum KL-6 levels of the PPT patients. No severe pirfenidone-related complications or IPF-related events occurred in the PPT patients, while six control patients developed AE-IPF (P = 0.0167). A quantitative histopathological evaluation of resected lung specimens found that tissue changes associated with IPF were significantly fewer in the PPT patients (P = 0.021). Conclusions: PPT is a feasible perioperative treatment for IPF patients with lung cancer. Its effectiveness in preventing postoperative AE-IPF thus warrants prospective verification.

UR - http://www.scopus.com/inward/record.url?scp=84941413610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941413610&partnerID=8YFLogxK

U2 - 10.1007/s00595-014-1071-5

DO - 10.1007/s00595-014-1071-5

M3 - Article

C2 - 25412984

AN - SCOPUS:84941413610

VL - 45

SP - 1263

EP - 1270

JO - Surgery Today

JF - Surgery Today

SN - 0941-1291

IS - 10

ER -